` GOVX (GeoVax Labs Inc) vs S&P 500 Comparison - Alpha Spread

GOVX
vs
S&P 500

Over the past 12 months, GOVX has underperformed S&P 500, delivering a return of -30% compared to the S&P 500's 7% growth.

Stocks Performance
GOVX vs S&P 500

Loading

Performance Gap
GOVX vs S&P 500

Loading
GOVX
S&P 500
Difference

Performance By Year
GOVX vs S&P 500

Loading
GOVX
S&P 500
Add Stock

Competitors Performance
GeoVax Labs Inc vs Peers

S&P 500
GOVX
ABBV
AMGN
GILD
VRTX
Add Stock

GeoVax Labs Inc
Glance View

Market Cap
13.8m USD
Industry
Biotechnology

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. The company is headquartered in Smyrna, Georgia. The firm is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The firm is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.

GOVX Intrinsic Value
Not Available
Back to Top